Zymeworks Inc. (ZYME) is a clinical-stage biopharmaceutical company that develops engineered, multifunctional antibody-based therapies, with its lead bispecific antibody zanidatamab (marketed as Ziihera) at the center of a growing, royalty-driven business. With shares trading around $25.50, the question is whether the stock can climb to the $41 level implied by Wall Street's published price targets.
Roughly 14 current analyst price targets were reviewed from firms that identify the analyst, firm, and target, with values clustering between a low of about $32 and a high of about $58. The calculated mean is approximately $41, which rounds to the central target of $41 used throughout this article. Ratings are overwhelmingly constructive, with the large majority at Buy or Overweight equivalents.
Recent activity underscores both the optimism and the spread in views. Truist raised its target to $34 in early October 2026, while TD Cowen initiated coverage at $34 after the Theravance acquisition closed. Citi moved to $39, J.P. Morgan to $33, and Wells Fargo, which upgraded the stock to Overweight, sits at $40. More bullish shops include B. Riley at $44, Evercore ISI at $44, Stifel at $46, Jefferies at $50, H.C. Wainwright at $55, and Leerink Partners at $58. The dispersion reflects different assumptions about the durability of zanidatamab royalties and the value of new pipeline assets.
At a recent close of $25.54, Zymeworks trades near the middle of its 52-week range of $16.00 to $31.34, with a market capitalization of roughly $1.8 billion. Moving to $41 implies about 61% upside, which is a very large move by any standard and well above the stock's prior 52-week high. The path would likely require a sustained re-rating driven by growing royalty revenue, not a single clinical catalyst. Notably, the company is projected to swing to positive EPS (earnings per share) in 2026, with revenue forecasts rising sharply, but near-term reported results remain weak as the model transitions.
The core support is zanidatamab's commercial trajectory. Positive HERIZON-GEA-01 data for Ziihera in HER2-positive gastric cancer and FDA approval milestones tied to partner Jazz Pharmaceuticals have driven repeated target increases. Analysts also point to Zymeworks' shift toward a higher-margin, royalty-focused model and early pipeline readouts from assets such as ZW191 and ZW251. The Theravance acquisition adds commercial infrastructure and a diversified revenue base, while the overwhelmingly bullish analyst stance provides a tailwind if execution matches expectations.
The most immediate obstacle is the company's own recent financial performance. Its latest quarterly report missed consensus on both earnings and revenue, with revenue down roughly 90% year over year as the business repositions. Biotech valuations also remain sensitive to interest rates, and Truist has cautioned that there is "less room for error into 2027," favoring names with visible revenue delivery. Competition in the HER2-targeted oncology space, potential royalty-stream concentration in a single asset, and the simple reality that a $41 level sits far above any prior trading history all present meaningful hurdles.
From a technical standpoint, the 52-week high of $31.34 is the clearest near-term resistance level, while the 52-week low of $16.00 marks durable support. The stock's 50-day simple moving average sits near $26.78, just above the current price, with the 200-day average around $25.63 below it, suggesting a stock consolidating in a broad range. A sustained move toward $41 would require clearing the $31 zone and holding well above it, a structural shift rather than a routine breakout.
Analyst price targets generally reflect a research horizon of about 12 months, though individual firms apply different assumptions and timelines. The next key catalyst is the company's earnings report, scheduled for early November 2026. Investors should watch revenue and royalty growth, updated guidance, further analyst target revisions, FDA and partner developments for zanidatamab, and early data on pipeline assets. Macroeconomic conditions, including interest-rate moves, will also shape the valuation multiple applied to a pre-earnings-growth biotech.
Tickeron's AI Daily Buy/Sell Signals uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals from shifting market conditions, technical behavior, and AI-driven analysis. For traders following names like Zymeworks, the tool can help surface changing momentum and emerging patterns before they are widely recognized. It is designed to help investors discover opportunities, monitor existing positions, and spot evolving trends more efficiently than manual chart review.
The $41 central target is an analyst-derived average reflecting a genuinely bullish but widely dispersed set of views. Reaching it would require roughly a 61% advance, a very large move that depends on zanidatamab's royalty stream maturing as modeled, successful integration of Theravance, and favorable pipeline readouts. The strongest supports are a consensus Buy bias, positive HER2 data, and a royalty-heavy model, while weak near-term results, valuation sensitivity, and a $32-to-$58 target range highlight the uncertainty. The target is a benchmark for what analysts collectively believe is possible, not a guaranteed outcome, and the coming earnings report and clinical updates will determine whether that path remains credible.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, ZYME has been loosely correlated with JAZZ. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if ZYME jumps, then JAZZ could also see price increases.
| Ticker / NAME | Correlation To ZYME | 1D Price Change % | ||
|---|---|---|---|---|
| ZYME | 100% | +4.48% | ||
| JAZZ - ZYME | 52% Loosely correlated | -0.84% | ||
| REPL - ZYME | 46% Loosely correlated | +2.63% | ||
| VSTM - ZYME | 44% Loosely correlated | -1.39% | ||
| ENTA - ZYME | 43% Loosely correlated | -3.08% | ||
| MLTX - ZYME | 40% Loosely correlated | +3.20% | ||
More | ||||